Antengene Corporation   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shanghai China (2016)

Organization Overview

First Clinical Trial
2018
NCT03591965
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Antengene Biologics Limited | Antengene Corporation | Antengene Discovery Limited | Antengene (Hangzhou) Biologics Co., Ltd. | Antengene Therapeutics Limited | Guoxue lane, Chengdu, Sichuan | Medical Monitor | Shanghai Antengene Corporation Limited

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Cholangiocarcinoma (Phase 1)

Chondrosarcoma (Phase 1)

Glioma (Phase 1)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, T-Cell (Phase 1)

Lymphoma, T-Cell, Peripheral (Phase 1)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 30
  • # of Trial APIs: 47